Reid Laurence
- SEC CIK
- 0001492749
In the past year, 1 open-market purchase filing worth $23.4K and no sales.
Current role at each company
- MGX Metagenomi Therapeutics, Inc.Directoras of Sep 11, 2026
- KALV KalVista Pharmaceuticals, Inc.Directoras of Jun 11, 2026
- DBTX Decibel Therapeutics, Inc.See Remarksas of Sep 25, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $23.4K
- 1 filing
- Sold
- –
- 0 filings
- Net
- +$23.4K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Reid Laurence as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
MGX Metagenomi Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 (view filing)7:51 PM ET | Sep 9 | 2 days | Reid LaurenceDirector | PPurchase | +20.0K | $1.17 | +$23.4K | New position20.0K after | 2 lots |
DBTX Decibel Therapeutics, Inc.
See Remarks1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 (view filing) | Sep 15 | 2 days | Reid LaurencePresident and Chief Executive | PPurchase | +10.0K | $7.64 | +$76.4K | +63.1%25.8K after |